DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/g7kd5x/investigation) has announced the addition of the "Investigation Report on China's Trastuzumab Market, 2010-2019" report to their offering.
Developed by Genentech, trastuzumab was approved by FDA to be used in the clinic in September 1998 under the trade name of Herceptin, a major product of Roche. In 2013, the sales value of trastuzumab was USD 6.56 billion around the world.
After entering China in 2002 for the treatment of HER2 metastatic breast cancer, trastuzumab developed fast with annual sales value rising from less than CNY 20 million in 2005 to CNY 577 million in 2014 and CAGR during this period reached up to 52.9%. Currently, trastuzumab in the Chinese market is monopolized by the subsidiary companies of Roche such as Genentech and Shanghai Roche Pharmaceutical Co., Ltd who has the largest market share of 80.60% with sales value in 2014 reaching up to CNY 465 million.
Due to its low toxicity and obvious therapeutic effects, trastuzumab can prolong patients' lives and improve the life quality of patients with advanced cancer, thus becoming the major driving force behind the growth of tumor monoclonal antibody market. The market size of trastuzumab in China is expected to keep expanding in the next few years.
Key Topics Covered:
1 Related Concepts of Trastuzumab
2 Market Profile of Trastuzumab in China
3 Survey on Sales Status of Trastuzumab in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Trastuzumab in China, 2010-2014
5 Survey on Dosage Forms of Trastuzumab in China, 2010-2014
6 Reference Price of Trastuzumab in Chinese Hospitals in 2014
7 Major Manufacturers of Trastuzumab in Chinese Market, 2010-2014
8 Market Outlook of Trastuzumab in China, 2015-2019
- Shanghai Roche Pharmaceutical Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/g7kd5x/investigation